A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

• Status: Terminated
• Trial end date: 2013-03-01

Summary

The purpose of this study is to determine if the addition of study drug (custirsen) can provide durable pain palliation for castrate resistant prostate cancer patients receiving docetaxel retreatment or cabazitaxel as a second line therapy.

• Phase: Phase 3

Details

• Lead Sponsor: Achieve Life Sciences; OncoGenex Technologies
• Collaborator: Teva Pharmaceuticals USA
• Treatments: Docetaxel; Prednisone